Real-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type 2 diabetes: The HYPOCRAS study

Diabetes and Metabolism

Volumn 38, Issue 6, 2012, Pages 550-557

  Penfornis, A ^a   Bourdel Marchasson, I ^b,c   Quere, S ^d   Dejager, S ^e  

^a Bâtiment Socrate   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d CNRS University Bordeaux Segalen   (France)

^e NOVARTIS PHARMA K K   (Japan)

Author keywords

DPP4 inhibitors; Elderly; Hypoglycaemia; Oral antidiabetic agents; Type 2 diabetes mellitus

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; METFORMIN; ORAL ANTIDIABETIC AGENT;

ADD ON THERAPY; AGED; ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRESCRIPTION; PROSPECTIVE STUDY; TREATMENT DURATION;

AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 84870689974     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2012.08.003     Document Type: Article

References (34)

1. Virally M., Blickle J.F., Girard J., Halimi S., Simon D., Guillausseau P.J. Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives. Diabetes Metab 2007, 33:231-244.
2. Bonaldi C., Vernay M., Roudier C., Salanave B., Oleko A., Malon A., et al. A first national prevalence estimate of diagnosed and undiagnosed diabetes in France in 18- to 74-year-old individuals: the French Nutrition and Health Survey 2006/2007. Diabetes Med 2011, 28:583-589.
3. Fagot-Campagna A., Bourdel-Marchasson I., Simon D. Burden of diabetes in an aging population: prevalence, incidence, mortality, characteristics and quality of care. Diabetes Metab 2005, 31(Spec no 2):5S35-52S.
4. Bourdel-Marchasson I., Berrut G. Caring the elderly diabetic patient with respect to concepts of successful aging and frailty. Diabetes Metab 2005, 31(Spec no 2):5S13-19S.
5. Amiel S.A., Dixon T., Mann R., Jameson K. Hypoglycaemia in type 2 diabetes. Diabetes Med 2008, 25:245-254.
6. Balkrishnan R., Rajagopalan R., Camacho F.T., Huston S.A., Murray F.T., Anderson R.T. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther 2003, 25:2958-2971.
7. Pornet C., Bourdel-Marchasson I., Lecomte P., Eschwège E., Romon I., Fosse S., et al. Trends in the quality of care for elderly people with type 2 diabetes: the need for improvements in safety and quality (the 2001 and 2007 ENTRED Surveys). Diabetes Metab 2011, 37:152-161.
8. Phung O.J., Scholle J.M., Talwar M., Coleman C.I. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010, 303:1410-1418.
9. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379.
10. Sinclair A.J., Paolisso G., Castro M., Bourdel-Marchasson I., Gadsby R., Rodriguez Mañas L. European diabetes working party for older people 2011 clinical guidelines for type 2 diabetes mellitus. Executive summary. Diabetes Metab 2011, 37(Suppl 3):S27-S38.
11. Efendic S., Portwood N. Overview of incretin hormones. Horm Metab Res 2004, 36:742-746.
12. Bourdel M.I., Doucet J., Bauduceau B., Berrut G., Blickle J.F., Brocker P., et al. Key priorities in managing glucose control in older people with diabetes. J Nutr Health Aging 2009, 13:685-691.
13. Bourdel-Marchasson I., Schweizer A., Dejager S. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. Hosp Pract 2011, 39:7-21.
14. Schwartz S.L. Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4-inhibitors. Am J Geriatr Pharmacother 2010, 8:405-418.
15. Doucet J., Chacra A., Maheux P., Lu J., Harris S., Rosenstock J. Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Curr Med Res Opin 2011, 27:863-869.
16. Pratley R.E., McCall T., Fleck P.R., Wilson C.A., Mekki Q. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc 2009, 57:2011-2019.
17. Barzilai N., Guo H., Mahoney E.M., Caporossi S., Golm G.T., Langdon R.B., et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 2011, 27:1049-1058.
18. Schweizer A., Dejager S., Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab 2009, 11:804-812.
19. Pratley R.E., Rosenstock J., Pi-Sunyer F.X., Banerji M.A., Schweizer A., Couturier A., et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care 2007, 30:3017-3022.
20. Halimi S., Raccah D., Schweizer A., Dejager S. Role of vildagliptin in managing type 2 diabetes mellitus in the elderly. Curr Med Res Opin 2010, 26:1647-1656.
21. Schweizer A., Dejager S., Foley J.E., Shao Q., Kothny W. Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population≥75years: a pooled analysis from a database of clinical trials. Diabetes Obes Metab 2011, 13:55-64.
22. Davis E.D., Morissey M., Peters J.R., Wittrup-Jensen K., Kennedy-Martin T., Currie C.J. Impact of hypoglycemia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Op 2005, 21:1477-1483.
23. Lundkvist J., Berne C., Bolinder B., Jonsson L. The economic and quality of life impact of hypoglycemia. Eur J Health Econ 2005, 6:197-202.
24. Defining and reporting hypoglycemia in diabetes. Diabetes Care 2005, 28:1245-1249. American Diabetes Association Workgroup on Hypoglycemia.
25. McEwen L.N., Bilik D., Johnson S.L., Halter J.B., Karter A.J., Mangione C.M., et al. Predictors and impact of intensification of antihyperglycemic therapy in type 2 diabetes: translating research into action for diabetes (TRIAD). Diabetes Care 2009, 32:971-976.
26. Bouée S., Detournay B., Balkau B., Blicklé J.F., Attali C., Vergès B., et al. Diabète de type 2 : pratiques d'intensification thérapeutique chez les médecins généralistes en France en 2008-2009. BEH 2010, 42-43:436-440.
27. Barnett A.H. Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy. Curr Med Res Opin 2010, 26:1333-1342.
28. Zhang Q., Marrett E., Jameson K., Meiler S., Davies M.J., Radican L., et al. Reasons given by general practitioners for non-treatment decisions in younger and older patients with newly diagnosed type 2 diabetes mellitus in the United Kingdom: a survey study. BMC Endocr Disord 2011, 11:7.
29. Vexiau P., Mavros P., Krishnarajah G., Lyu R., Yin D. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. Diabetes Obes Metab 2008, 10(Suppl. 1):16-24.
30. Alvarez G.F., Tofe P.S., Krishnarajah G., Lyu R., Mavros P., Yin D. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study. Diabetes Obes Metab 2008, 10(Suppl. 1):25-32.
31. Arem R. Hypoglycemia associated with renal failure. Endocrinol Metab Clin North Am 1989, 18:103-121.
32. Bremer J.P., Jauch-Chara K., Hallschmid M., Schmid S., Schultes B. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care 2009, 32:1513-1517.
33. Budnitz D.S., Lovegrove M.C., Shehab N., Richards C.L. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011, 365:2002-2012.
34. Bron M., Marynchenko M., Yang H., Yu A.P., Wu E.Q. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs. Postgrad Med 2012, 124:124-132.